EX VIVO STEM CELL EXPANSION FROM UMBILICAL CORD BLOOD

来自脐带血的体外干细胞扩增

• 批准号: 7605067
• 负责人: CHRISTOPHER J HOGAN
• 金额: $ 9.43万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605067
• 关键词: Adult; Blood Banks; Blood Platelets; Bone Marrow; Cell Fraction; Computer Retrieval of Information on Scientific Projects Database; Condition; Funding; Goals; Grant; Harvest; Hematopoietic; Hematopoietic System; Institution; Marrow; Numbers; Patients; Research; Research Personnel; Resources; Source; Stem cells; Time; Transplantation; Umbilical Cord Blood; Umbilical Cord Blood Transplantation; United States National Institutes of Health; in vivo; neutrophil; reconstitution

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Umbilical cord blood is an alternative source for stem cells in patients undergoing myeloablative therapies and requiring hematopoietic reconstitution. It is particularly attractive when considering that there is a greater than 85% chance that an HLA-matched cord blood unit can be found for patients in one of the cord blood banks world-wide, whereas chances of finding a match from the National Donor Marrow Bank are ~25%. Unfortunately the number of stem cells contained in a cord blood unit is orders of magnitude less than can be harvested from an adult bone marrow. Consequently the times to neutrophil and platelet independence in patients following a cord blood transplantation are 3-4 times greater compared to a transplantation performed with a bone marrow product. The goal of this study is to isolate stem cells from umbilical cord blood and to devise culture conditions that will allow the stem cell fraction to expand with a corresponding expansion of the ability to reconstitute and maintain the hematopoietic system in vivo.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 脐带血是接受脊髓损伤疗法并需要造血重建的患者的干细胞的替代来源。 考虑到在全球一家脐带血库中找到HLA匹配的脐带血单位的可能性超过85％的可能性，这一点尤其有吸引力，而在全球范围内，有可能从国家捐助者骨髓银行找到一场比赛的机会约为25％。 不幸的是，脐带血单位中包含的干细胞数量比从成年骨髓收获的数量级要小。 因此，与用骨髓产物进行的移植相比，脐带血移植后患者的中性粒细胞和血小板独立性的时间高3-4倍。 这项研究的目的是将干细胞从脐带血中分离出来，并设计培养条件，从而使干细胞分数随着体内重建和维持造血系统的相应扩展而扩展。